Compare

Lonza Group AG/€LONN

1D1W1M3M6MYTD1Y5YMAX

About Lonza Group AG

Lonza Group AG is a global company specializing in pharmaceutical, biotech, and nutrition sectors, headquartered in Basel, Switzerland. It provides integrated solutions for the creation of new drugs, ranging from active pharmaceutical ingredients (APIs) and drug formulation to drug delivery systems. The company serves a diverse clientele including pharmaceutical and biotech companies, offering contract development and manufacturing organization (CDMO) services. With operations in multiple countries, Lonza is strategically positioned to cater to global healthcare needs. Known for its extensive capabilities in cell and gene therapy, the organization leverages advanced technology platforms to support complex biopharmaceutical developments, enhancing its competitive edge in the industry.
Ticker
€LONN
Sector
Health
Primary listing
XGAT
Employees
20,141
Headquarters
Basel, Switzerland
Website
www.lonza.com

Lonza Group AG Metrics

BasicAdvanced
€48B
-
-€1.70
0.81
€5.47
0.40%

What the Analysts think about Lonza Group AG

Analyst ratings (Buy, Hold, Sell) for Lonza Group AG stock.
Analyst projections of the future price of Lonza Group AG stock.

Bulls say / Bears say

Lonza’s first-half 2026 sales grew 16% at constant exchange rates and core EBITDA rose 27.4%, leading it to raise its full-year margin outlook to 33–34%. Growth came from every business platform, giving evidence of broad operating momentum. (Lonza)
At its October capital markets day, Lonza lifted its medium-term growth ambition to 10–13% a year and targeted a core EBITDA margin in the high thirties. If it delivers, the combination of growth and improved margins could drive earnings higher. (Reuters)
Lonza is adding commercial-scale ADC filling capacity in Stein under a long-term customer agreement. That committed demand supports its push to capture growth in complex antibody-drug conjugate manufacturing. (Lonza)
Lonza expects growth and profitability to moderate in the second half of 2026 as business timing shifts and year-on-year comparisons become tougher. That could make the near-term growth profile look less impressive after a strong first half. (Reuters)
Vacaville, a key biologics site, is expected to have broadly flat sales through 2028, with meaningful growth only later. The delay leaves investors waiting for a major capacity investment to contribute more materially. (Reuters)
Lonza expects a 2–3% foreign-exchange drag on 2026 sales growth and plans organic capital spending at a mid-to-high-teens share of sales. Currency pressure and ongoing investment could limit reported growth and slow cash generation in the near term. (Lonza)
Data summarised monthly by Lightyear AI. Last updated on 15 Oct 2026.

Lonza Group AG Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Lonza Group AG Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Lonza Group AG

AllEURUSDGBP
Funds
Fund name
Fund size
€LONN weighting
HSBC MSCI Europe Islamic Screened$HIEU
€144M1.72%
HSBC MSCI Europe Islamic Screened£HIPS
€144M1.72%
SPDR MSCI World Health Care$WHEA
$708M0.61%
SPDR MSCI World Health Care£HEAW
$708M0.61%
Xtrackers MSCI World Health Care$XDWH
$4.1B0.60%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.